Reason for request
Inclusion on list of products reimbursed by National Insurance and for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of FIRMAGON is substantial. |
Clinical Added Value
| no clinical added value |
In the context of the current strategy for treatment of advanced prostate cancer, with a combination of a Gn-RH analogue and an antiandrogen in the first month of treatment, FIRMAGON provides no improvement in actual benefit (IAB level V). |
eNq1mFFv2jAQx9/5FFEe9kZSSqF0S6g21m5Ircbaok17QSa5gFmw07MNdJ9+hoBKJ0ddDZZ4IXb+d/adf/4r0eVqnnsLQEE5i/1GcOJ7wBKeUjaJ/eHDdb3jX3Zr0YwsyPO0Uz0vaDR8L8mJELG/Hg3GQJgIft7efAb9PqDfrXkRH88gkS/mKUnz4CsR01tSrOd40YLT1JuDnPI09gslN0+9SEjUWXSXHH+LgiQQhdsn+6Oz0dn+8yhci/2HqhKAN4RNjKLArDQThQhM9oiECceninybVtpU3IHgChMYEDkdIF/QFFJjiIzkAqyCZMv0HnCRg1wHMYqHs2QurMTJjKzu4LFvTvqjHu3Jlayf1BvnF/p3dt5qNdstq1C4t1XmKuhFhMmo026fd5ohsDCjOCcTzixrM+AoSe6oKlT0XjaWozgIj69WP6WiyMlTMBOF7VYRJHoYUB9/dwtZr+ABNZByvWf/6DOV5+Ebsx5uceEo4zWNelwxWUGN4b3tRvQ4k7Cqrqgd6ORq24sUxPFk/3BmhvxAjXOa2CJNQ0eBkMO7fjXRjgmDT0TAEN3R4AdlKV+K41Nmv6qOsi82oDSKFpg2RqcXnXaj1bI+RL90C1XcMFcKeQGh5g8Vh2ClzzJ+KFB0V5qldj15tHbc+ByekBwqnE7dki26D3fGzFmnuztF5YBR9MvVg217fFeAT/ebv0Zpmsa7wtpx1wXMdS++lnd5auNi1DxpdS6aZ+/IvPiwc9CxpVsuRZ2YZYVmxEylLMT7MFwul8GUiLogej+DDKuvgEvj0o+xfM3b52q68/NO7v/SD5WsdZT6uLxE31ZG23P7mkM41PVu39+6a2MMiQoOqEWJeGcg7l8dn+3PltdZ2oMXiHEXZmNPiaScubJNamxUPOg20WVl16j58C3LaMXnlcq2jMLy0063FoXrzzrd2l8dXgE1
tx9CTsvtrK55NncZ
